NBIX
Neurocrine Biosciences, Inc.
Drug Manufacturers - Specialty & Generic · Healthcare · United States
146.38
close · 2026-10-29
value
25
cheaper than peers25
quality
98
stronger fundamentals98
ranked against
Drug Manufacturers - Specialty & Generic
value
quality
41 peerswide variation
Value inputs
| measure | company | vs peers |
| forward P/E | 12.23× | 45 |
| price to book | 4.03× | 39 |
| EV to EBITDA | 20.91× | 31 |
| price to sales | 6.01× | 20 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| revenue growth | 42.2% | 91 |
| debt to equity | 13.6% | 87 |
| return on equity | 22.5% | 81 |
| operating margin | 22.8% | 76 |
4 of 4 measures available
Facts
| market cap | $15B |
| free cash flow | $590.6M |
| employees | 2,000 |
| first trade | 1996-05-23 |
| next earnings | 2026-11-02 |
| fundamentals updated | 2026-07-30 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | 4.67 | 3.29 | 2.47 | 1.56 |
| free cash flow | $748.7M | $557.2M | $361.6M | $322.9M |
| net income | $478.6M | $341.3M | $249.7M | $154.5M |
| revenue | $2.86B | $2.36B | $1.89B | $1.49B |
| unusual items | -$21.4M | -$61.4M | -$115.5M | -$39.2M |